Progressive macular hypomelanosis showing excellent response to oral isotretinoin

Kim, Young Jin; Lee, Dong Yoon; Lee, Ji Yeoun; Yoon, Tae Young

doi:10.1111/j.1346-8138.2012.01605.x

Cited by 10 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several treatment modalities are used against PMH including topical benzoylperoxide 5% (BPO) and clindamycin 1% alone or in combination with ultraviolet A (UVA) or narrow band ultraviolet B (UVB) irradiation [4–7], oral lymecycline in combination with topical BPO 5% for 3 months [8], and low-dose isotretinoin for 1 month [9]; however, the ideal treatment is not yet defined.…”

Section: Introductionmentioning

confidence: 99%

Propionibacterium acnes phylogenetic type III is associated with progressive macular hypomelanosis

Petersen

Scholz

Jensen

et al. 2017

EuJMI

View full text Add to dashboard Cite

Progressive macular hypomelanosis (PMH) is a skin disorder that is characterized by hypopigmented macules and usually seen in young adults. The skin microbiota, in particular the bacterium Propionibacterium acnes, is suggested to play a role.Here, we compared the P. acnes population of 24 PMH lesions from eight patients with corresponding nonlesional skin of the patients and matching control samples from eight healthy individuals using an unbiased, culture-independent next-generation sequencing approach. We also compared the P. acnes population before and after treatment with a combination of lymecycline and benzoylperoxide.We found an association of one subtype of P. acnes, type III, with PMH. This type was predominant in all PMH lesions (73.9% of reads in average) but only detected as a minor proportion in matching control samples of healthy individuals (14.2% of reads in average). Strikingly, successful PMH treatment is able to alter the composition of the P. acnes population by substantially diminishing the proportion of P. acnes type III.Our study suggests that P. acnes type III may play a role in the formation of PMH. Furthermore, it sheds light on substantial differences in the P. acnes phylotype distribution between the upper and lower back and abdomen in healthy individuals.

show abstract

Section: Introductionmentioning

confidence: 99%

Propionibacterium acnes phylogenetic type III is associated with progressive macular hypomelanosis

Petersen

Scholz

Jensen

et al. 2017

EuJMI

View full text Add to dashboard Cite

show abstract

“…In 2012, Kim et al described a patient with PMH treated with low-dose isotretinoin for 1 month, inducing complete remission (Kim, Lee, Lee, & Yoon, 2012). This case report describes a patient with PMH who was unsuccessfully treated with oral isotretinoin.…”

mentioning

confidence: 96%

Unsuccessful treatment of progressive macular hypomelanosis with oral isotretinoin

Damevska

Pollozhani

Neloska

et al. 2017

Dermatologic Therapy

View full text Add to dashboard Cite

“…At 1‐month follow‐up of isotretinoin 10 mg once a day used for his rosacea, a considerable improvement in the lesions of PMH was observed. No relapse was seen over a 10‐month follow‐up (Kim, Lee, Lee, & Yoon, ).…”

Section: Indications Of Low‐dose Isotretinoin In Dermatologymentioning

confidence: 99%

Low dose of isotretinoin: A comprehensive review

Abdelmaksoud

Lotti

Anadolu

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Isotretinoin is a first‐generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti‐inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date‐unlimited PubMed search, from inception till December 2019, using the following search terms: “low‐dose isotretinoin” and “dermatology,” “isotretinoin and safety,” “isotretinoin, off‐label uses,” “isotretinoin and male fertility,” “isotretinoin, iPLEDGE system,” aiming to deliver a therapeutic update relevant to clinical practice. All English‐language articles were considered with no limitation based on the articles' type. Low‐dose isotretinoin is not limited to old and novel dermatological conditions, but also showed promising results in the field of infertility and safety in the field of gastroenterology. We also highlight on the safety profile of the drug and experts' recommendations to enhance safety measures to decrease fetal risk while on isotretinoin.

show abstract

Progressive macular hypomelanosis showing excellent response to oral isotretinoin

Cited by 10 publications

References 5 publications

Propionibacterium acnes phylogenetic type III is associated with progressive macular hypomelanosis

Propionibacterium acnes phylogenetic type III is associated with progressive macular hypomelanosis

Unsuccessful treatment of progressive macular hypomelanosis with oral isotretinoin

Low dose of isotretinoin: A comprehensive review

Contact Info

Product

Resources

About